Our results showed that the experimental group had significantly lower levels of IL-4 and IL-5 after treatment, suggesting a reduction in the Th2-type inflammatory response, which plays a central role in the pathophysiology of BA. This evidence concerns the gene IL5 and breast angiosarcoma.